Street View: Johnson & Johnson may be able to weather tariff scare
Drug and Medical device maker Johnson & Johnson JNJ.N beat Q1 estimates on strong sales of its cancer treatments, including multiple myeloma medicine Darzalex
Median PT of 26 brokerages covering the stock is $169.50 - LSEG data
LOOKS SOMEWHAT IMMUNE DESPITE TARIFFS
J.P.Morgan ("neutral," PT: $185) expects co to maintain steady growth, despite concerns about litigation and tariffs impacting sales in China
RBC ("outperform," PT: $181) believes co is well-positioned for growth in MedTech due to its strong portfolio and innovation, particularly in heart failure treatments, electrophysiology, and surgical robotics
TD Cowen ("buy," PT: $185) believes co can manage $400 mln tariff costs and still meet its 2025 earnings goals, which mainly affects its MedTech products shipped from the U.S. to China
Morgan Stanley ("equal-weight," PT: $169) see JNJ's strategic investments as a positive move despite tariff impact
Related Articles
National Debt Bomb Ignited? Musk Warns U.S. Will Be 1000% Bankrupt Without AI
TradingKey - Tesla (TSLA) CEO Elon Musk recently issued another warning regarding the rapidly ballooning U.S. national debt. He stated clearly that without artificial intelligence and robotics, the United States will inevitably head toward fiscal bankruptcy.
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 market
